Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01518907 · ClinicalTrials.gov registry record · Phase 1
The Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
A Phase 1 study of Cellulite and Edematous Fibrosclerotic Panniculopathy, sponsored by Endo Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 99
- Enrollment target
- 1
- Study location
NCT01518907: Completed Phase 1 study of Cellulite and Edematous Fibrosclerotic Panniculopathy, sponsored by Endo Pharmaceuticals.
NCT01518907 is a Phase 1 study of Cellulite and Edematous Fibrosclerotic Panniculopathy that has completed, run by Endo Pharmaceuticals. The registered enrollment target is 99 participants, below the 152-participant average among 5 other Cellulite trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01518907, a Phase 1 study of Cellulite and Edematous Fibrosclerotic Panniculopathy, has completed, sponsored by Endo Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 99 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the safety, effectiveness, pharmacokinetics, and immunogenicity of AA4500 at increasing doses and concentrations in the treatment of adult women with cellulite.
Conditions Studied
Interventions
- BIOLOGICAL COLLAGENASE CLOSTRIDIUM HISTOLYTICUM
Study Locations (1)
Maryland
- SNBL Clinical Pharmacology Center, Inc - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2012-01 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
What the finished NCT01518907 record still lists
NCT01518907 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 152-participant average among 5 other Cellulite trials with a reported enrollment target (35% lower).
The record links to 2 conditions, with Cellulite appearing as the primary indexed condition, and to 1 intervention - of which COLLAGENASE CLOSTRIDIUM HISTOLYTICUM is the first listed.
NCT01518907 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT01518907 about?
NCT01518907 is a clinical study titled "The Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)". This study will evaluate the safety, effectiveness, pharmacokinetics, and immunogenicity of AA4500 at increasing doses and concentrations in the treatment of adult women with cellulite.
What is the current status of trial NCT01518907?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 99 participants. The study started on 2012-01. Estimated completion is 2013-02.
What conditions does trial NCT01518907 study?
This clinical trial studies the following conditions: Cellulite, Edematous Fibrosclerotic Panniculopathy.
What interventions are being tested in trial NCT01518907?
The interventions under investigation include: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM (BIOLOGICAL).
Who is sponsoring clinical trial NCT01518907?
This trial is sponsored by Endo Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01518907 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cellulite
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Minimally Invasive Active Release of Septa Bands for Cellulite and Connective Tissue Release for Fibrosis Treatment in Body Contouring Surgery
RECRUITING · NA
-
Cyrolipolysis vs Cyrolipolysis and Subcision for Cellulite
ACTIVE NOT RECRUITING · NA
-
Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks
COMPLETED · Phase 2
-
A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2)
COMPLETED · Phase 2
-
Long-Term Study of EN3835 (CCH-aaes) in Edematous Fibrosclerotic Panniculopathy (Cellulite)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia